RxDoctor Payments Data

Mark Rapp

Neurology · Inwood, NYNPI 1285131961

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,662 of the $2,148 with a category attached, or 77.4%. Amgen accounts for 77.4% of it on its own, with 4 other manufacturers making up the rest.

$2,148in general payments, 2019–2025

Across 9 payments — averaging $238.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • F. Hoffmann-la Roche AG$194
  • Biogen$149
  • E.r. Squibb & Sons, L.L.C.$116
  • AstraZeneca$28
$2,099,190in research payments, 2019–2025

Across 19 payments — averaging $110,484 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Molecular Systems, Inc.$2.1M
  • E.r. Squibb & Sons, L.L.C.$45K

What the payments were for

  • Travel & lodging$1,66277%
  • Food & beverage$48623%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,148 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Other neurology in Inwood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →